Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.

Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.

While the clinical benefit of MEK inhibitor (MEKi)-based therapy is well established in Raf mutant malignancies, its utility as a suppressor of hyperactive MAPK signaling in the absence of mutated Raf or Ras, is an area of ongoing research. MAPK activation is associated with loss of ERα expression a...

Full description

Bibliographic Details
Main Authors: June Y Hou, Alicia Rodriguez-Gabin, Leleesha Samaraweera, Rachel Hazan, Gary L Goldberg, Susan Band Horwitz, Hayley M McDaid
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3563537?pdf=render

Internet

http://europepmc.org/articles/PMC3563537?pdf=render

Similar Items